Some Medicare beneficiaries will soon have access to costly drugs for $50 a month
Beneficiaries are advised to talk to their healthcare provider.
Mason Reed 
A massive price cut is coming for Medicare beneficiaries seeking access to highly sought-after weight loss medications. The Centers for Medicare and Medicaid Services (CMS) recently unveiled a new initiative that drops the cost of these treatments to just a fraction of their standard sticker price.
Affordable Access for Seniors
Under the new program, individuals enrolled in Medicare Part D prescription drug plans can secure a one-month supply of certain weight loss drugs for only $50. This initiative, known as the Medicare GLP-1 Bridge, is scheduled to launch on July 1 and will remain available to eligible participants through December 31, 2027.
“These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost,” CMS Administrator Dr. Mehmet Oz said in a statement. “The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible, while advancing our broader goal of helping Americans live healthier lives.”
Included Medications and Savings
The program covers a variety of popular medications, including Foundayo, Wegovy (available in both injections and tablets), and Zepbound’s KwikPen. Beneficiaries are advised to speak with their healthcare providers to determine if these GLP-1 treatments are appropriate for their specific health needs.
This update represents a substantial financial shift for users who often face monthly costs ranging from $900 to $1,400 for these drugs. By capping the price at $50, the program aims to remove the high-cost barrier for seniors across the country.
For more details on how to participate, you can see more on the program here.
